Loading... Please wait... Loading... Please wait...
ESTIMATED
11/06/2023
11/06/2023
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | $1.58 | $1.58 | $1.58 |
| Q2 2024 | 0 | $1.34 | $1.34 | $1.34 |
| Q3 2024 | 0 | $1.54 | $1.54 | $1.54 |
Aridis Pharmaceuticals, Inc. last posted its earnings results on Monday, November 6th, 2023. The company reported $-0.02 earnings per share for the quarter, topping analysts' consensus estimates of $-0.1 by $0.08. The company had revenue of 417,000 for the quarter and had revenue of 0 for the year. Aridis Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-1.64 diluted earnings per share) and currently has a price-to-earnings ratio of 0.48. Aridis Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, July 2nd, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 11/06/2023 | Q3 2023 | -$0.10 | -$0.00 | 0.1 | $1.50 M | $417,000 | 09/13/2023 | Q2 2023 | $0.34 | $19.65 M | 06/08/2023 | Q1 2023 | -$0.24 | $0 | 05/22/2023 | Q4 2022 | -$0.24 | $0 | 11/21/2022 | Q3 2022 | -$0.15 | -$0.51 | -0.36 | $690,184 | $0 | 08/15/2022 | Q2 2022 | -$0.06 | -$0.46 | -0.4 | $30,855 | $292,000 | 05/16/2022 | Q1 2022 | -$0.51 | -$0.46 | 0.05 | $0 | 04/13/2022 | Q4 2021 | -$0.71 | $570,000 | 11/10/2021 | Q3 2021 | -$0.54 | -$1.69 | -1.15 | $738,166 | $98,000 | 08/12/2021 | Q2 2021 | -$0.57 | -$0.49 | 0.08 | $33,000 | $33,000 | 05/11/2021 | Q1 2021 | -$0.60 | -$0.67 | -0.07 | $0 | 03/30/2021 | Q4 2020 | -$0.59 | $0 | 11/23/2020 | Q3 2020 | -$0.65 | $0 | 08/11/2020 | Q2 2020 | -$0.72 | -$0.47 | 0.25 | $1.57 M | $1.00 M | 05/12/2020 | Q1 2020 | -$0.62 | -$0.73 | -0.11 | $0 | 04/08/2020 | Q4 2019 | -$0.63 | $-1,022,000 | 11/13/2019 | Q3 2019 | -$0.86 | -$0.87 | -0.01 | $0 | 08/12/2019 | Q2 2019 | -$1.09 | -$1.03 | 0.06 | $0 | 05/14/2019 | Q1 2019 | -$0.82 | -$0.99 | -0.17 | $1.02 M | 03/28/2019 | Q4 2018 | -$0.67 | $1.39 M |
|---|
A. Aridis Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, July 2nd, 2024 based off last year's report dates.
A. In the previous quarter, Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) reported $-0.02 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.1 by $0.08.
A. The conference call for Aridis Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Aridis Pharmaceuticals, Inc.'s latest earnings report can be read online.
A. Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) has a recorded net income of $0. Aridis Pharmaceuticals, Inc. has generated $-1.64 earnings per share over the last four quarters.
A. Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) has a price-to-earnings ratio of 0.48 and price/earnings-to-growth ratio is 0.01.
